- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05998135
Genanvendelse af Atovaquone til behandling af platinresistent ovariecancer
Fase II klinisk forsøg med genanvendelse af atovaquon til behandling af platinresistent ovariecancer
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To determine progression free survival of twenty-eight patients with platinum-resistant ovarian cancer treated with atovaquone.
SECONDARY OBJECTIVES:
I. To determine clinical benefit rate (complete response, partial response or stable disease) at six months.
II. To determine overall survival. III. To quantitate the on-target STAT3 inhibitory effect of atovaquone on STAT3-dependent gene transcription.
IV. To quantitate changes of the tumor immune infiltrate by inhibition of STAT3 with atovaquone.
OUTLINE:
Patients receive atovaquone orally (PO) on study. Patients also undergo computed tomography (CT) and biopsy or paracentesis throughout the study.
After completion of study treatment, patients are followed up for 30 days and then every 6 month thereafter.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Namita Khanna, MD, MSPH
- Telefonnummer: 404-778-3401
- E-mail: namita.khanna@emory.edu
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Nina Kimball
- Telefonnummer: 404-778-8145
- E-mail: nina.cathleen.dobbs.kimball@emory.edu
-
Kontakt:
- Maisey S Ratcliffe
- Telefonnummer: 404-778-3449
- E-mail: maisey.shannon.ratcliffe@emory.edu
-
Ledende efterforsker:
- Namita Khanna, MD, MSPH
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
- Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- There will be no limitations on number of prior lines of therapy
- Trial is open to non-English speaking patients
- Trial is open to patients referred from community practice
Exclusion Criteria:
- Patients who are < 18 years old
- Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
- Patients who are incarcerated
- Patients who are unable to provide consent / lack decision-making capacity
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (atovaquone)
Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study. |
Undergo CT
Andre navne:
Undergo biopsy
Andre navne:
Undergo paracentesis Given PO
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression free survival (PFS)
Tidsramme: From initiation of atovaquone to progression or death, assessed up to 1 year
|
Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median PFS will be estimated using the Brookmeyer-Crowley approach. |
From initiation of atovaquone to progression or death, assessed up to 1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical benefit rate
Tidsramme: At 6 months
|
Clinical benefit rate is defined as complete response, partial response, and/or stable disease at six months. Clinical response will be assessed every 6 weeks for the first 24 months and every 12 weeks thereafter using Response Evaluation Criteria in Solid Tumors 1.1 criteria. Will be estimated as a proportion, with an exact 95% confidence interval estimated using the Clopper-Pearson method. |
At 6 months
|
|
Overall survival (OS)
Tidsramme: From diagnosis to death from any cause, where patients who are alive will be censored at last follow-up date, assessed up to 1 year
|
OS will be estimated using the Kaplan-Meier method, and median survival will be calculated. A 95% confidence interval will be estimated using the Brookmeyer-Crowley approach. |
From diagnosis to death from any cause, where patients who are alive will be censored at last follow-up date, assessed up to 1 year
|
|
Incidence of adverse events
Tidsramme: Up to 30 days
|
Safety will be determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5. Frequencies and percentages will be used to summarize safety events. |
Up to 30 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Namita Khanna, MD, MSPH, Emory University Hospital/Winship Cancer Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Organiske kemikalier
- Undersøgelsesteknikker
- Terapeutik
- Håndtering af eksemplar
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Punkteringer
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Polycykliske forbindelser
- Diagnostiske teknikker, kirurgisk
- Quinones
- Naphthoquinoner
- Dræning
- Atovaquon
- Biopsi
- Paracentese
Andre undersøgelses-id-numre
- STUDY00005363
- P30CA138292 (U.S. NIH-bevilling/kontrakt)
- STUDY00005363 (Anden identifikator: Emory University)
- NCI-2023-03479 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- WINSHIP5782-22 (Anden identifikator: Emory University)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .